Condition |
Trial Name |
Sponsor |
Solid Tumors |
1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors |
Boehringer Ingelheim |
Solid Tumors |
1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors |
Mirati Therapeutics, Inc. |
Rectal Cancer |
19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma |
Memorial Sloan Kettering Cancer Center |
Chronic Myelogenous Leukemia |
ASC2ESCALATE: Asciminib Monotherapy as First or Second Line Treatment |
Novartis Pharmaceuticals |
Breast Cancer |
ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer |
Gilead Sciences |
Breast Cancer |
ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer |
Gilead Sciences |
Breast Cancer |
ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer |
Gilead Sciences, Inc. |
Cachexia in Colorectal or Pancreatic Cancer |
AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy |
AVEO Pharmaceuticals, Inc. |
Solid Tumors |
BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors |
Boehringer Ingelheim |
Breast Cancer |
BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer |
BriaCell Therapeutics Corporation |
Solid Tumor or Lymphoma |
CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
CStone Pharmaceuticals |
Non-Small Cell Lung Cancer |
EIK1001-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer |
Eikon Therapeutics |
Breast Cancer |
ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor |
Stemline Therapeutics, Inc. |
Diffuse Large B-Cell Lymphoma or Follicular Lymphoma |
EPCORE: Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma |
AbbVie Inc. |
Central Nervous System Cancer |
F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy |
Fore Biotherapeutics |
Solid Tumors |
F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors |
Fore Biotherapeutics |
Breast Cancer |
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer |
Regor Pharmaceuticals Inc. |
Gastric or Gastroesophageal Junction Cancer |
GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
AstraZeneca |
Head and Neck Squamous Cell Carcinoma |
GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC |
Gilead Sciences, Inc. |
Colorectal Cancer |
INTRINSIC: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer |
Hoffmann-La Roche |
Non-Small Cell Lung Cancer |
KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation |
Mirati Therapeutics, Inc. |
Solid Tumors |
KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors |
Mirati Therapeutics Inc. |
Colon or Rectal Cancer |
LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash |
Lutris Pharma Ltd. |
Non-Hodgkin Lymphoma |
MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies |
Genentech, Inc. |
Hyperkalemia/Chronic Kidney Disease |
NYH-01: Hyperkalemia/Chronic Kidney Disease |
Relypsa |
Breast Cancer |
OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor |
Olema Pharmaceuticals, Inc. |
Solid Tumors |
PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor |
Aadi Bioscience, Inc. |
Non-Small Cell Lung Cancer |
Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
Regeneron Pharmaceuticals |
ITP, wAIHA, CAD |
RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias |
Alpine Immune Sciences, Inc. |
Breast Cancer |
SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression |
AstraZeneca |
Solid Tumors |
STELLAR-009: Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab |
Exelixis |
Solid Tumors |
TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study |
Hoffmann-La Roche |
Non-Small Cell Lung Cancer |
TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer |
Daiichi Sankyo, Inc. |
Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer |
K-Group, Beta, Inc. |
Cancer Diagnosis |
[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients |
Memorial Sloan Kettering Cancer Center |
Various Indications |
[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) |
Precision for Medicine |
Solid Tumors |
[Sample Collection] Collection and Distribution of Biofluids for Research Purposes |
Bluestar Genomics |
Solid Tumors |
[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) |
Exact Sciences Thrive LLC |
Various Indications |
[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) |
MT Group |
Various Indications |
[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) |
SERATRIALS, LLC. |
Solid Tumors |
[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening |
Freenome Holdings Inc. |
Solid Tumors |
eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion |
Merus N.V. |